Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Acasti Pharma Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
ACST
Nasdaq
2834
https://www.acasti.com/en
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Acasti Pharma Inc
12 Best Biotech Penny Stocks to Invest In
- Mar 24th, 2024 7:54 pm
Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights
- Feb 12th, 2024 1:00 pm
Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial
- Feb 1st, 2024 1:00 pm
Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?
- Dec 25th, 2023 11:56 am
Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024
- Dec 13th, 2023 1:00 pm
Acasti Announces Second Quarter 2024 Financial Results and Business Highlights
- Nov 13th, 2023 1:00 pm
Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial
- Oct 23rd, 2023 12:00 pm
Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)
- Oct 4th, 2023 12:00 pm
Acasti Announces $7.5 Million Private Placement Equity Financing
- Sep 26th, 2023 12:00 pm
Acasti to Participate in the H.C. Wainwright Global Investment Conference
- Sep 6th, 2023 12:00 pm
TEVA to Pay $225 Million to Settle Price-Fixing Charges (Revised)
- Aug 23rd, 2023 7:49 am
TEVA to Pay $250 Million to Settle Price-Fixing Charges
- Aug 22nd, 2023 1:19 pm
Acasti Announces First Quarter 2024 Financial Results and Business Highlights
- Aug 11th, 2023 11:00 am
Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting
- Aug 9th, 2023 8:05 pm
Dr. Reddy's (RDY) Q1 Earnings and Revenues Beat Estimates
- Jul 28th, 2023 12:02 pm
Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients
- Jul 10th, 2023 1:00 pm
Acasti Pharma Announces 1-for-6 Reverse Stock Split
- Jul 7th, 2023 12:00 pm
Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023
- Jul 5th, 2023 1:00 pm
Acasti Pharma Reports Fiscal Year 2023 Operational Results
- Jun 23rd, 2023 11:00 am
Acasti Announces Appointment of New Scientific Advisory Board Members
- Jun 22nd, 2023 1:00 pm
Scroll